New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry Robert Spandorfer1, Kevin Kane2, George Reed2, Dimitrios Pappas2, Joel Kremer2, Jeffrey Curtis3 and Iris Navarro-Millán4, 1

A Prediction Model For Switching of Biologics and TsDMARDs in Rheumatoid Arthritis Laura Capelli, George Reed, Joel Kremer, EULAR

Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients Dimitrios Pappas1, George Reed2, Kevin Kane2, Jeffrey Curtis3 and Joel Kremer4

Ocon T, Albany Medical College. Influence of corticosteroid cumulative dose on cardiovascular events in patient with rheumatoid arthritis. In preparation for manuscript submission.

Baker J. U of Pennsylvania. Influence of disease activity on cardiovascular disease in patient with rheumatoid arthritis. In preparation for manuscript submission.

Curtis JR, Palmer L, Reed G, Greenberg JD, Pappas D, Harrold L, Kremer J. Real-world outcomes associated with triple therapy vs TNFi combo therapy: Results from the Corrona registry. Poster 2018 ACR, being prepared for manuscript submission.

JM Kremer, JL Palmer, GW Reed, D Pappas, LR Harrold, JD Greenberg, JR Curtis
Clinical and Sociodemographic Characteristics of Patients with Rheumatoid Arthritis (RA) Starting Triple Therapy and a Combination of a TNF Inhibitor and Methotrexate from a Large US Registry
Conclusion: Utilization of Triple was not common over a period of 16 years covered by the registry. Pts started on triple were older, had less severe RA and a higher comorbidity burden. These differences are likely to impact response to treatment as it appears that rheumatologists channeled pts with more severe RA to TNFi + MTX, while pts with a h/o comorbidities were more likely to receive Triple.
Poster Presented at ACR 2018.

JR Curtis, L Palmer, G Reed, JD Greenberg, D Pappas, L Harrold, J Kremer
Real-World outcomes associated with Triple Therapy vs. TNFi Combo Therapy: Results from the Corrona Registry
Conclusion: Based on real world evidence from a large U.S. RA registry, use of Triple is uncommon, and outcomes associated with Triple are less favorable compared to combination therapy with TNFi+MTX.
Poster Presented at ACR 2018.

Kremer JM, Palmer JL, Reed GW, Pappas D, Harrold LR, Greenberg JD, Curtis JR. Clinical and sociodemographic characteristics of patient with rheumatoid arthritis starting triple therapy and a combination of a TNF inhibitor and methotrexate from a large US registry. Poster 2018 ACR, being prepared for manuscript submission.

Birju D Bhatt, JL Palmer, JR Curtis, JM Kremer.
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis in patients with PsA, there was a significant positive relationship between blood pressure and both psoriasis BSA and joint disease activity, measured by CDAI. We also conclude that clinically, the initiation of TNFi did decrease blood pressure, but the decrease was not significant. We believe that this is the first study to look at relationships between the initiation of TNFi treatment and blood pressure in PsA patients.
Poster presented at ACR 2017.

Bhatt D, Albany Medical College, Palmer JR, Curtis JR, Kremer JM. Changes in blood pressure with TNF inhibitors in patients with psoriatic arthritis. Poster 2017 ACR, in preparation for manuscript submission.

JR Curtis, L Harrold, J Kremer, JL Palmer
Higher Multi Biomarker Disease Activity Scores Foreshadow Greater Longitudinal Improvement in RA Disease Activity
Among RA patients with high baseline disease activity (measured by CDAI) and who started a new medication for RA, patients with high MBDA scores (>44) were associated with significantly greater improvement in the CDAI over time compared to those with high CDAI and lower MBDA scores. The MBDA test may be useful to select patients who subsequently have a better response to treatment and thus provide utility even beyond clinical assessments of RA disease activity such as CDAI.
Poster presented at ACR 2016.

A Ogdie, JL Palmer, JD Greenberg, LR Harrold, DH Solomon, A Kavanaugh, J Kremer, JR Curtis, PJ Mease.
Predictors of response to TNF alpha inhibitors among patients with psoriatic arthritis.
Female sex, obesity, higher CDAI at baseline, hypertension and previous biologic use were predictors of not achieving remission whereas college education (or higher) was associated with remission. Similar predictors were identified for achieving low disease activity.
Poster presented at ACR 2016.

LC Cappelli, JL Palmer, CO Bingham
Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis
Patients treated with TCZ had improvement in a variety of disease activity measures at initial follow up, regardless of serologic status. This remained true when adjusted for baseline disease activity level and disease duration and regardless of definition used for serologic status (RF vs CCP vs either positive). The results suggest that TCZ may be equally useful in seronegative and seropositive patients, unlike some other biologic DMARDs.
Poster presented at ACR 2016.

LR Harrold, JL Palmer, JR Curtis, D Pappas, JD Greenberg, JM Kremer
Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis. Using the U.S. Corrona registry, the proportion of RA patients achieving LDA when initiating a biologic in moderate or high disease activity has increased over time.
Poster presented at EULAR 2016 (updated from ACR2015)

LR Harrold, JL Palmer, JR Curtis, JD Greenberg, JM Kremer
Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis. Using the U.S. Corrona registry, the proportion of RA patients achieving LDA when initiating a biologic in moderate or high disease activity has increased over time.
Poster presented at ACR 2015

Harrold LR, Palmer JL, Curtis JR, Greenberg JD, Kremer JM. Trends over time in achievement of low disease activity among biologic initiators with rheumatoid arthritis. Poster ACR 2015.